0001209191-21-005797.txt : 20210127
0001209191-21-005797.hdr.sgml : 20210127
20210127205827
ACCESSION NUMBER: 0001209191-21-005797
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210125
FILED AS OF DATE: 20210127
DATE AS OF CHANGE: 20210127
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BENEVICH ERIC
CENTRAL INDEX KEY: 0001643653
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22705
FILM NUMBER: 21561728
MAIL ADDRESS:
STREET 1: C/O NEUROCRINE BIOSCIENCES, INC.
STREET 2: 12790 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC
CENTRAL INDEX KEY: 0000914475
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 330525145
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 617-7600
MAIL ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-01-25
0
0000914475
NEUROCRINE BIOSCIENCES INC
NBIX
0001643653
BENEVICH ERIC
12780 EL CAMINO REAL
SAN DIEGO
CA
92130
0
1
0
0
Chief Commercial Officer
Common Stock
2021-01-25
4
M
0
3477
41.78
A
20882
D
Common Stock
2021-01-25
4
S
0
3477
120.0251
D
17405
D
Common Stock
2021-01-25
4
S
0
1600
120.0275
D
15805
D
Common Stock
2021-01-26
4
M
0
300
41.78
A
16105
D
Common Stock
2021-01-26
4
S
0
300
120.00
D
15805
D
Common Stock
2021-01-26
4
S
0
100
120.00
D
15705
D
Non-Qualified Stock Option
41.78
2021-01-25
4
M
0
3477
41.78
D
2025-06-01
Common Stock
3477
56523
D
Non-Qualified Stock Option
41.78
2021-01-26
4
M
0
300
41.78
D
2025-06-01
Common Stock
300
56223
D
The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.00 to $120.07. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.00 to $120.04. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Option granted June 1, 2015 and vested at 25% upon first anniversary (June 1, 2016) and remaining 75% vested in 36 equal monthly installments beginning July 1, 2016.
/s/ Darin Lippoldt, Attorney-in-Fact
2021-01-27